Patents by Inventor Mark Bernard

Mark Bernard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES
    Publication number: 20140341892
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 20, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
  • Anti-alpha2 integrin antibodies and their uses
    Patent number: 8759009
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: June 24, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES
    Publication number: 20110135635
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: August 17, 2010
    Publication date: June 9, 2011
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • Anti-?2 integrin antibodies and their uses
    Patent number: 7807794
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: October 5, 2010
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • Anti-alpha2 integrin antibodies and their uses
    Publication number: 20070128190
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: November 17, 2006
    Publication date: June 7, 2007
    Inventors: Elias Lazarides, Catherine Woods, Mark Bernard
  • System and method for facilitating a transaction through binding comparison shopping using a communications network
    Publication number: 20020002531
    Abstract: A method for facilitating a transaction that includes receiving information describing an offer presented to a user; receiving an indication that the user desires to accept the offer unless a better offer is available, and accept the better offer when the better offer is available; providing the offer information for delivery to a system having access to information describing the other available offers, being adapted to compare the offer information with the other available offer information to determine whether the better offer is available, being adapted to provide information related to the determination, and being adapted to accept the better offer on behalf of the user when the better offer is available; and receiving the determination information and providing the determination information for delivery to an interested party, the determination information comprising an indication that the better offer has been accepted by the system.
    Type: Application
    Filed: May 29, 2001
    Publication date: January 3, 2002
    Inventors: Andrew Lustig, Jeffrey Isaac, Mark Bernard